Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH 43205, USA.
The Heart Center, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Biomolecules. 2021 Jan 27;11(2):166. doi: 10.3390/biom11020166.
Extracorporeal life support provides perfusion for patients with heart failure to allow time for recovery, function as a bridge for patients to heart transplantation, or serve as destination therapy for long term mechanical device support. Several biomarkers have been employed in attempt to predict these outcomes, but it remains to be determined which are suitable to guide clinical practice relevant to extracorporeal life support. Galectin-3 and soluble suppression of tumorigenicity-2 (sST2) are two of the more promising candidates with the greatest supporting evidence. In this review, we address the similarities and differences between galectin-3 and sST2 for prognostic prediction in adults and children with heart failure requiring extracorporeal life support and highlight the significant lack of progress in pediatric biomarker discovery and utilization.
体外生命支持为心力衰竭患者提供灌注，使其有时间恢复，也可作为心脏移植患者的桥梁，或作为长期机械装置支持的终末期治疗。已经有几种生物标志物被用于预测这些结果，但仍需确定哪些标志物适合指导与体外生命支持相关的临床实践。半乳糖凝集素-3 和可溶性肿瘤抑制因子-2（sST2）是最有前途的候选标志物之一，具有最大的支持证据。在这篇综述中，我们讨论了半乳糖凝集素-3 和 sST2 在预测需要体外生命支持的心力衰竭成人和儿童患者预后方面的异同，并强调了儿科生物标志物发现和应用方面缺乏重大进展。
